News

ICAAC: 2015 brings three major systematic reviews of diabetic foot infection therapy

Publish date: September 26, 2015

 

EXPERT ANALYSIS FROM ICAAC 2015

References

Dr. Peters reported having no financial conflicts regarding his presentation.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

When stepping up type 2 treatment, GLP-1 agonists have the edge
MDedge Family Medicine
EASD: SGLT2 inhibitor empagliflozin cuts CV risk in patients with type 2 diabetes
MDedge Family Medicine
‘Artificial beta-cell’ insulin systems post more positive data
MDedge Family Medicine
Diabetic foot ulcer: Early closure post debridement best
MDedge Family Medicine
Empagliflozin’s triumph respins FDA’s diabetes drug mandate
MDedge Family Medicine
Study links childhood type 1 diabetes to increased AD risk
MDedge Family Medicine
In type 2 diabetes, pump therapy costs more but saves much
MDedge Family Medicine
EASD: SGLT2 inhibitors show potential in 1DM despite DKA concern
MDedge Family Medicine
EASD: Pre-pregnancy weight, not gestational gain, affects later diabetes risk
MDedge Family Medicine
Long-acting insulin degludec – and degludec combo drug – win FDA nod
MDedge Family Medicine